ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ginkgo buys Warp Drive genome-mining platform

by Lisa M. Jarvis
May 18, 2019 | APPEARED IN VOLUME 97, ISSUE 20

 

Months after acquiring Warp Drive Bio, Revolution Medicines has sold the biotech firm’s genome-mining platform to Ginkgo Bioworks, a Boston-based synthetic-biology firm. Warp Drive has amassed sequencing data for more than 135,000 bacterial strains, a library that researchers sift through in search of clusters that encode for specific structural elements of compounds. Ginkgo says it will continue work related to a 2017 antibiotics drug-discovery pact established between Roche and Warp Drive.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment